成都下肢静脉曲张治疗要多钱成都治疗肝血管瘤的专业医院,成都手术治疗大隐静脉曲张费用,成都腿静脉曲张怎么治疗价格,成都在找哪家医院治疗血管瘤,成都得了脉管炎要怎么治疗,治了血管精索静脉曲张医院成都,成都治前列腺肥大医院哪家好

BEIJING, March 24 (Xinhuanet) -- A new study has found that Actos, a medicine treats onset diabetes, could also reduce the diabetes risk in people with prediabetes.The study, which was published Wednesday in New England Journal of Medicine, followed 602 prediabetics whose obesity, ethnicity, family history and other factors put them at high risk of developing diabetes.The research findings showed that Actos, generically known as pioglitazone, reduced the odds of developing Type 2 diabetes by 72 percent in people with prediabetes.Only 2.1 percent of those who took Actos developed diabetes each year over the three years of the study, compared with 7.6 percent of those who took a placebo.Lead author of the study Ralph DeFronzo said, "The 72 percent reduction is the largest decrease in the conversion rate of pre-diabetes to (Type 2) diabetes that has ever been demonstrated by any intervention, be it diet, exercise or medication."However, Actos can have significant side effects, including water retention, moderate weight gain, and increased risk of bone fractures.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

SAN FRANCISCO, April 5 (Xinhua) -- The appeal of tablet computer and electronic-book reader (e-reader) has been giving a boost to semiconductor market as sales of chips for such devices surged in 2010 and keeps growing, market research firm International Data Corp. (IDC) said on Tuesday.A new IDC report showed that worldwide revenues for media tablet and e-reader semiconductors grew by over 2,000 percent to 3. 3 billion U.S. dollars in 2010 as semiconductor suppliers enabled original equipment manufacturers to bring new products to market less than 8 months after Apple Inc. launched its iPad tablet.According to IDC's definition, media tablets are devices with color displays larger than 5-inch and smaller than 14-inch, running lightweight operating systems and able to be based on either x86 or ARM processors."The opportunity for semiconductors in media tablets and e- readers has exploded and semiconductor suppliers are scrambling to bring to market semiconductor and software platforms to enable these products," Michael Palma, a senior research analyst at IDC, said in a statement.Looking forward, IDC said it expects media tablet and e-reader semiconductor revenues to grow by 120 percent year over year in 2011, predicting that the market will be boosted by the arrival of a new version of Google Inc.'s Android operating system, dual core processors and increased bandwidth."For the next several years, we will see rapid innovation cycles for products launched into the marketplace and semiconductor suppliers will continue to satisfy evolving end user requirements over the coming years," Palma noted.

LOS ANGELES, April 2 (Xinhua) -- People taking antidepressants may be more likely to develop thicker arteries which may raise the risk of heart disease and stroke, a new study suggests.Depression can heighten the risk for heart disease, but the effect of antidepressant use is separate and independent from depression itself, according to the study make public by the American Association for the Advancement of Science (AAAS) on Saturday.The data suggest that antidepressants may combine with depression for a negative effect on blood vessels, said study first author Amit Shah, MD, a cardiology fellow at Emory University School of Medicine.Study findings will be presented on April 5 at the American College of Cardiology meeting in New Orleans, according to the AAAS.The study included 513 middle-aged male twins who both served in the U.S. military during the Vietnam War. Twins are genetically the same but may be different when it comes to other risk factors such as diet, smoking and exercise, so studying them is a good way to distill out the effects of genetics.Researchers measured carotid intima-media thickness - the thickness of the lining of the main arteries in the neck -- by ultrasound. Among the 59 pairs of twins where only one brother took antidepressants, the one taking the drugs tended to have higher carotid intima-media thickness (IMT), even when standard heart disease risk factors were taken into account.The effect was seen both in twins with or without a previous heart attack or stroke. A higher level of depressive symptoms was associated with higher IMT only in those taking antidepressants."One of the strongest and best-studied factors that thickens someone's arteries is age, and that happens at around 10 microns per year," Shah said. "In our study, users of antidepressants see an average 40 micron increase in IMT, so their carotid arteries are in effect four years older."Antidepressants' effects on blood vessels may come from changes in serotonin, a chemical that helps some brain cells communicate but also functions outside the brain, Shah said."I think we have to keep an open mind about the effects of antidepressants on neurochemicals like serotonin in places outside the brain, such as the vasculature. The body often compensates over time for drugs' immediate effects," Shah said. " Antidepressants have a clinical benefit that has been established, so nobody taking these medications should stop based only on these results. This isn 't the kind of study where we can know cause and effect, let alone mechanism, and we need to see whether this holds up in other population groups."